ReviewClinical and translational radiation oncology2018
Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?
Review in Clinical and translational radiation oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence of human papillomavirus in head and neck cancer patients in India: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Pooled it
- Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Pooled it
- Pooled it
- Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Trial
- Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.European journal of cancer (Oxford, England : 1990) · 2020Trial
- Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol.Clinical and translational radiation oncology · 2026Article
- Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV-Positive Head and Neck Carcinoma.Cancer science · 2026Article
- Individual patient-reported symptom items discriminate imaging-graded dysphagia in head and neck cancer patients treated with radiotherapy: secondary analysis of pooled prospective studies.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026Article
- Optimizing the therapeutic ratio: a narrative review of de-escalation and response-adapted strategies in series including human papillomavirus negative head and neck cancer.Translational cancer research · 2026Review
- Patient experience and shared decision-making in HPV-positive oropharyngeal cancer: A systematic review of qualitative and quantitative evidence.Clinical and translational radiation oncology · 2025Review
- Article
- Artificial intelligence-based virtual staining platform for identifying tumor-associated macrophages from hematoxylin and eosin-stained images.European journal of cancer (Oxford, England : 1990) · 2025Article
- The influence of tobacco use, hazardous drinking, and other risk factors on HPV-associated oropharyngeal cancer risk and screening perceptions among gay and bisexual men: a cross-sectional study.BMC oral health · 2025Article
- Review
- Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas.British journal of cancer · 2025Article
- Analysis of Swallowing Functional Preservation by Surgical Versus CRT After Induction Chemotherapy for Oropharyngeal Cancer.Cancers · 2024Article
- Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile.Ecancermedicalscience · 2024Article
- β-CATENIN is a positive prognostic marker for HPV-positive head and neck squamous cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.British journal of cancer · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.